UNSPSC 51294416: Aripiprazole cavoxil

This classification denotes an antipsychotic agent C30H39Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SE284EQRL, chemically known as (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl hexanoate, but more generally known as aripiprazole cavoxil, which bears US NIH Compound Identifier 49831462. Most nations, for tariff and trade purposes, schedule aripiprazole cavoxil under HS 29337900 and SITC 51561.

As of Q4 2014, ARIPIPRAZOLE CAVOXIL remains US FDA's Preferred Term for this commodity. SMILES: CCCCCC(=O)OCN1C2CC(CCC2CCC1=O)OCCCCN3CCN(CC3)C4CCCC(C4CL)CL.

UNSPSC 51294416 Aripiprazole cavoxil is a Commodity code that nominally describes pharmaceutical products, but the recent state and local procurement activity under this code does not align with the code's stated scope. The sole recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems, which fall outside the aripiprazole antipsychotic medication category. This mismatch suggests either a coding error in the state and local procurement system or that the code is being used inconsistently to capture emergency-response pharmaceutical and harm-reduction products.

The single available opportunity shows Seminole County procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. The contract includes a two-year initial term with an optional one-year renewal, and vendors must meet E-Verify compliance, drug-free workplace certification, and applicable insurance requirements. Because the recent-opportunities block contains only one record and it does not match the code's nominal scope, the code shows little actionable activity for aripiprazole-focused business development. Firms pursuing pharmaceutical procurement with state and local health departments should verify code assignments independently rather than rely on this taxonomy entry.